MDxHealth SA — FY2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone Q4 filing; the supplied text does not provide separate fourth-quarter results. Financial statements are prepared under IFRS as issued by the IASB and amounts below are U.S. dollars unless stated otherwise.
Business context
MDxHealth is a commercial-stage precision diagnostics company focused primarily on prostate cancer testing in the United States. Its marketed tests are ConfirmMDx, used after a negative prostate biopsy, and SelectMDx, intended to help assess biopsy risk. ConfirmMDx generated approximately 91% of 2021 revenue. The company began trading ADSs on Nasdaq in November 2021; each ADS represents 10 ordinary shares.
Financial and operating performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $22.239 million | $18.460 million |
| Gross profit / margin | $10.564 million / 47.5% | $8.044 million / 43.6% |
| Operating loss | $26.841 million | $27.123 million |
| Net loss | $29.002 million | $28.662 million |
| Loss per share, basic and diluted | $0.24 | $0.34 |
| Net cash used in operating activities | $22.548 million | $20.244 million |
- Revenue increased 20%, attributed to higher test volumes and average selling price. Test volumes rose 3% year over year for both ConfirmMDx and SelectMDx, to 15,324 and 13,615, respectively.
- Gross margin improved 3.9 percentage points, primarily from higher average selling prices. R&D expense increased 47% to $6.673 million, mainly due to pipeline investment. Selling and marketing expense rose 6% to $17.744 million; general and administrative expense was broadly flat at $14.149 million.
- Other operating income was $1.161 million, including $659,000 of U.S. grant income and $382,000 of Dutch government grants. Financial expense increased to $2.172 million, principally reflecting debt and lease interest.
- Cash and cash equivalents were $58.498 million at year-end, versus $15.953 million a year earlier. Current assets were $66.606 million and current liabilities $16.432 million. Equity was $46.899 million, up from $5.849 million.
- Loans and borrowings totaled $12.092 million at year-end; lease liabilities were $3.464 million. Contractual payments for loans and leases totaled $15.556 million, including $5.281 million due within one year. Trade receivables were $4.582 million; reported DSO improved to 49 days from 55.
- Financing cash inflow was $66.498 million, primarily from the January private placement and November U.S. IPO. The IPO raised $45.0 million gross and approximately $40.2 million net; the private placement raised €25.0 million gross.
Changes versus comparable periods
Revenue grew from $18.460 million in 2020 and $11.785 million in 2019. Despite the 2021 revenue and gross-margin gains, net loss was slightly higher than in 2020, while operating loss narrowed modestly. Operating cash use increased by $2.304 million, which management attributed primarily to unfavorable working-capital movements. The large increase in year-end cash chiefly reflects equity financing, rather than internally generated cash.
COVID-19 continued to weigh on demand: versus 2019 pre-pandemic volumes, 2021 ConfirmMDx and SelectMDx billed volumes remained 16% and 37% lower, respectively. The filing also notes that a 2019 change in collection assumptions reduced 2019 revenue by $10.078 million, affecting comparisons with that year.
Outlook, risks and unusual items
- Management expects continuing net losses and significant cash outflows for at least the next 12 months, but believes year-end cash and anticipated product-sale cash flows are sufficient for at least that period. This assessment depends on forecasts and possible cost reductions. The filing identifies the losses and cash use as conditions that could raise doubt about going concern; the statements nevertheless use the going-concern basis.
- No specific revenue or earnings guidance is provided. Management expects investment in R&D and operating costs to continue; R&D and public-company costs may rise. Future profitability depends on test adoption, reimbursement, and successful commercialization of existing and pipeline products.
- Medicare covers ConfirmMDx under a final local coverage determination. SelectMDx did not yet have Medicare coverage: a May 2021 draft foundational LCD supported clinical utility, but final coverage and reimbursement remained pending. Commercial coverage is also uncertain.
- Revenue is highly concentrated in ConfirmMDx and U.S. customers. Medicare accounted for more than 38% of revenue in 2021 (approximately $8.51 million). COVID-related patient access, clinician engagement, laboratory capacity, and supply disruptions remain risks.
- The Kreos secured loan bears a 9.5% stated interest rate, with monthly principal and interest payments scheduled to resume in August 2022 and maturity in October 2023. It is secured by substantially all assets, including intellectual property, and includes restrictive covenants. The stated effective interest rate is 19.56%.
- In 2021, the company recognized grant income and fair-value adjustments; it recorded no impairment charge for the year. Earlier periods included significant impairment charges, including $5.1 million of intangible-asset impairment in 2019. The company’s revenue estimates depend on historical collections; insufficient collection history can result in cash-basis recognition.
- NovioGendix sellers disputed milestone payments, claiming approximately $880,000 was due. MDxHealth disagreed; the sellers indicated they might pursue arbitration. The company recorded $1.617 million of contingent liabilities at year-end and reported no other pending material legal proceedings.
- Other material risks include FDA or legislative changes affecting laboratory-developed tests, patent expiration and competition, billing audits and reimbursement delays, and potential dilution from future financing. The company reported an accumulated deficit of $244.302 million and $305.022 million of tax-loss carryforwards; no deferred tax asset was recognized.
Important facts for investors to verify
- Whether SelectMDx receives a final Medicare coverage determination, at what reimbursement level, and whether commercial payor coverage expands.
- Subsequent test volumes and revenue mix, particularly ConfirmMDx concentration and recovery of volumes from pre-pandemic levels.
- Actual cash burn, working-capital trends, financing needs, and the timing of loan repayments relative to management’s stated runway.
- Compliance with Kreos covenants and the effect of secured debt, convertible amounts, and potential equity dilution.
- Outcome of the NovioGendix milestone dispute and any arbitration or resulting payments.
- Progress, costs, and clinical evidence for pipeline products and the PRIORITY study, including any delays or results affecting adoption.